{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-022862","form_type":"8-K","ticker":"RNXT","cik":"0001574094","company_name":"RenovoRx, Inc.","filed_at":"2023-06-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.470638+00:00","generated_at":"2026-06-13T14:53:10.423343+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"RenovoRx announces positive interim Phase III data: RenovoGem delays progression by 8 months in pancreatic cancer","bullets":["Interim Phase III data show RenovoGem delays cancer progression by 8 months in locally advanced pancreatic cancer.","RenovoRx issued press release on June 29, 2023 detailing positive interim results from ongoing trial.","RenovoGem is delivered via RenovoRx's proprietary targeted therapy platform for difficult-to-treat cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-022862","json":"https://secwatch.observer/filing/0001493152-23-022862.json","markdown":"https://secwatch.observer/filing/0001493152-23-022862.md","text":"https://secwatch.observer/filing/0001493152-23-022862.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574094/000149315223022862/0001493152-23-022862-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574094/000149315223022862/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T14:53:10.423343+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}